Global Peptide Therapeutics Market

Peptide Therapeutics Market Size, Share, Growth Analysis, By Type (Generic, Innovative), By Type of Manufacturers (In-house, Outsourced), By Synthesis Technology, By Route of Administration, By Application, By Region - Industry Forecast 2025-2032


Report ID: SQMIG35H2072 | Region: Global | Published Date: December, 2024
Pages: 213 | Tables: 152 | Figures: 78

Peptide Therapeutics Market News

  • In August 2024, cGMP peptide manufacturing capacity was completed at a pharmaceutical manufacturing facility in Yangzhou, China. The move was triggered by the investment from Aurisco Pharmaceutical to expand the production of Aurisco’s generic GLP-1 peptides.  
  • In February 2024, a new company entered the peptide therapeutics market with around USD 28 million in funding. Orbis Medicines was launched with the intention of developing macrocyclic peptides for a wide variety of disease indications. Novo Holdings and Forbion led the financial seed raise round for Orbis.  
  • Back in December 2023, SynCrest Inc. In collaboration with Otsuka Chemical Co., Ltd., and Yokogawa Electric Corp. announced the launch of its CDRMO services for peptide therapeutics. Through this announcement, the company made its services accessible to pharmaceutical organizations working in South America, Japan, North America, and Europe. 
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Peptide Therapeutics Market size was valued at USD 40.69 billion in 2022 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). 

Peptide therapeutics providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for different diseases indications will also be a preferred strategy for new as well as leading peptide therapeutics companies. Taking advantage of supportive government initatives to promote medical R&D will also create new opportunities in the future. 'Eli Lilly and Company ', 'Amgen Inc. ', 'Pfizer Inc. ', 'Bristol-Myers Squibb Company ', 'Novo Nordisk A/S ', 'Takeda Pharmaceutical Company Limited ', 'AstraZeneca PLC ', 'Sanofi SA ', 'GlaxoSmithKline PLC ', 'Novartis AG ', 'Zealand Pharma A/S ', 'AmbioPharm Inc. ', 'Bachem Holding AG ', 'PolyPeptide Group ', 'Circle Pharma, Inc. ', 'PeptiDream Inc. ', 'Apitope Technology Ltd. ', 'Ever Neuro Pharma GmbH ', 'Teva Pharmaceuticals Industries Ltd. ', 'Arch Biopartners Inc.'

Poor lifestyle choices and growing adoption of unhealthy habits have lead to a major surge in incidence of chronic diseases around the world. As prevalence of diabetes, cancer, and other diseases rises, so does the need for better treatment for the same also rises. Low toxicity of peptide therapeutics makes them a preferred choice for treatment for multiple chronic diseases.  

Development of Oral Peptide therapeutics: Peptide therapeutics companies can focus on the development of oral peptide therapeutics which are currently not widely available in the market. Heavy investments in research would be required to develop peptide therapeutics that can be administered orally but will pay of big time for any company who dives into this  peptide therapeutics market trend going forward.  

North America is estimated to secure the top spot when it comes to the peptide therapeutics market. Increasing incidence of chronic diseases and high investments in medical research are forecasted to be the key factors contributing to the dominance of this region. Presence of key pharmaceutical manufacturers, rising awareness regarding benefits of peptide therapeutics, and supportive government funding to boost medical R&D are also expected to bolster sales of peptide therapeutics in this region. The United States is projected to lead the demand for peptide therapeutics in North America followed by Canada.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Peptide Therapeutics Market

Report ID: SQMIG35H2072

$5,300
BUY NOW GET FREE SAMPLE